SIK1 suppresses colorectal cancer metastasis and chemoresistance via the TGF-β signaling pathway

Yuan Gao, Hongming Li, Ping Wang, Junjiang Wang, Xueqing YaoJournal of Cancer 2023 · DOI

TL;DR

This study reveals that the protein SIK1 acts as a tumor suppressor in colorectal cancer (CRC) by inhibiting metastasis and oxaliplatin resistance. SIK1 achieves this by interacting with Smad7 to suppress the TGF-β signaling pathway, which in turn reduces epithelial-mesenchymal transition (EMT) and cell migration.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a significant health challenge, with a substantial portion of patients experiencing metastasis and resistance to chemotherapy, leading to poor survival rates. While the TGF-β signaling pathway is known to play a complex role in cancer progression, promoting invasion and resistance, the specific molecular mechanisms underlying these processes are not fully understood. Furthermore, identifying novel therapeutic targets that can simultaneously address metastasis and chemoresistance is crucial. This paper investigates the role of Salt-Inducible Kinase 1 (SIK1), a protein previously implicated in tumor suppression in other cancers, within the context of CRC, specifically focusing on its potential to counteract metastasis and drug resistance.

Methods

The researchers employed a multi-pronged approach to investigate SIK1's role in CRC:

  • Expression Analysis: Western blotting was used to assess SIK1 protein levels in CRC cell lines and patient tissues, comparing them to normal controls.
  • Functional Assays:
    • Migration and Invasion: Transwell assays and wound-healing assays were conducted to evaluate the ability of CRC cells to migrate and invade after manipulating SIK1 expression.
  • Proliferation: CCK-8 assays and colony formation assays were used to assess cell proliferation and growth.
  • Chemoresistance: Cytotoxicity assays (measuring IC50 values) were performed to determine the sensitivity of CRC cells to oxaliplatin, a common chemotherapy drug, after altering SIK1 levels.
  • Pathway Analysis: KEGG pathway analysis (using GSEA) was performed on gene expression data to identify signaling pathways associated with SIK1 expression in CRC.
  • Molecular Interactions: Co-immunoprecipitation (Co-IP) assays were used to confirm the physical interaction between SIK1 and Smad7.
  • In Vivo Studies: A mouse model of CRC was established to evaluate the effect of SIK1 knockdown on tumor growth, metastasis, and chemotherapy response.
  • Pharmacological Inhibition: The TGF-β signaling inhibitor galunisertib (LY2157299) was used to investigate the rescue effect on SIK1's functions.

Datasets

  • Human Colorectal Cancer (CRC) Tissues: 10 pairs of CRC tissue and adjacent normal tissue were collected from patients.
  • CRC Cell Lines: A panel of human colorectal cancer cell lines (RKO, SW480, M5, SW620, CACO2, DLD1, HCT116, LOVO) and an immortalized colonic cell line (FHC) were used.
  • OXA-resistant Cell Lines: HCT116R and SW620R cell lines were used or generated.
  • TCGA Database: Data from The Cancer Genome Atlas (TCGA) was analyzed for promoter methylation levels of SIK1 in CRC and for prognostic value of SIK1 expression.
  • GEO Database (GSE101896): Gene expression data was utilized for KEGG pathway analysis.

Key Insights and Ideas

  • SIK1 as a Tumor Suppressor in CRC: Contrary to some cancer contexts, SIK1 appears to act as a protective factor in CRC, with its expression being generally reduced in cancer cells.
  • The TGF-β Pathway is Central: The study strongly implicates the TGF-β signaling pathway as the primary mediator of SIK1's tumor-suppressive effects in CRC. This pathway is known for its dual role in cancer, and SIK1's intervention here is a key finding.
  • Smad7 is a Direct Interactor: The direct physical interaction between SIK1 and Smad7, a known inhibitor of TGF-β signaling, provides a concrete molecular mechanism for SIK1's action. This interaction is crucial for understanding how SIK1 dampens the pathway.
  • Inhibition of EMT is Key: SIK1's ability to suppress EMT, a process critical for cancer cell migration and invasion, is a major takeaway. This links SIK1's action to a fundamental mechanism of metastasis.
  • Dual Action on Metastasis and Chemoresistance: The paper demonstrates that SIK1 not only hinders cell migration and invasion but also reverses resistance to oxaliplatin, a common chemotherapy drug. This dual action makes SIK1 a particularly attractive therapeutic target.
  • Rescue by TGF-β Inhibitor: The observation that the effects of SIK1 knockdown could be reversed by a TGF-β inhibitor (galunisertib) further solidifies the central role of this pathway.

Key Results

  • Reduced SIK1 Expression: SIK1 protein expression was significantly lower in CRC cell lines and tissues compared to normal controls.
  • SIK1 Overexpression Inhibits Migration and Invasion: Upregulating SIK1 in RKO and SW480 cells significantly reduced their migratory and invasive abilities.
  • SIK1 Knockdown Promotes Migration and Chemoresistance: Knocking down SIK1 in HCT116 cells increased their migration and invasion, and importantly, conferred resistance to oxaliplatin.
  • SIK1 Interacts with Smad7: Co-IP experiments confirmed a direct binding interaction between SIK1 and Smad7.
  • SIK1 Suppresses TGF-β Signaling and EMT Markers: SIK1 overexpression led to decreased phosphorylation of Smad2 and reduced expression of EMT markers (N-cadherin, Snail) and pro-metastatic genes (FN, PAI-1). Conversely, SIK1 knockdown had the opposite effect.
  • In Vivo Efficacy: In a mouse model, SIK1 knockdown led to increased tumor weight and volume, and reduced efficacy of oxaliplatin chemotherapy, highlighting SIK1's role in both metastasis and drug response in a living system.
  • Galunisertib Reverses SIK1 Knockdown Effects: Treatment with galunisertib partially restored the migratory and invasive abilities of SIK1-knockdown cells and reversed oxaliplatin resistance.

Limitations and Future Work

  • Limited Proliferation Effect: The study notes that SIK1 had little effect on cell proliferation in vitro, suggesting its primary role in CRC is related to metastasis and chemoresistance rather than direct tumor growth inhibition.
  • Mechanism of EMT and Chemoresistance Interaction: While the paper suggests a link between EMT and oxaliplatin resistance, the specific mechanisms of this interaction require further in-depth investigation.
  • In Vivo Rescue Experiments: While in vivo experiments demonstrated SIK1's role, further studies could explore the rescue effects of SIK1 restoration or TGF-β inhibition in the in vivo setting.
  • Broader Therapeutic Strategies: The authors suggest that future research should focus on fully characterizing the underlying mechanisms and validating these findings in animal models, paving the way for SIK1 as a potential therapeutic target for CRC. The potential for combining SIK1-based therapies with existing treatments warrants exploration.

Summary updated

Abstract

In the present study, we investigated the role of salt-induced kinase 1 (SIK1), a serine/threonine kinase protein, in colorectal cancer (CRC). Despite the reported association of SIK1 with tumor malignancy suppression in various cancers, limited research has been conducted on its function in CRC. Our findings revealed that SIK1 expression was low in CRC cells. The results of a KEGG pathway analysis showed a strong association between SIK1 and the TGF-β signaling pathway. In addition, a coimmunoprecipitation assay validated the interaction between SIK1 and Smad7. Our data indicate that SIK1 inhibited the phosphorylation of Smad2, a critical molecule in the Smad-related TGF-β pathway, and downstream target genes of the TGF-β pathway. Furthermore, SIK1 was found to inhibit indicators of epithelial-mesenchymal transition (EMT) and reverse oxaliplatin resistance in CRC. Additionally, SIK1 reduced cell migration and invasion. Our results suggest that the inhibitory effect of SIK1 on the TGF-β pathway contributes to the suppression of metastasis and oxaliplatin chemoresistance in CRC. However, this effect was reversed by galunisertib (LY2157299). In conclusion, our findings provide novel insights into the role of SIK1 in the regulation of the TGF-β pathway in CRC, suggesting its potential as a therapeutic target for the treatment of CRC. Further studies are required to fully characterize the mechanism underlying these observations and to validate these findings in animal models.
BibTeX
@article{gao2023sik,
  author = {Yuan Gao and Hongming Li and Ping Wang and Junjiang Wang and Xueqing Yao},
  title = {{SIK1 suppresses colorectal cancer metastasis and chemoresistance via the TGF-β signaling pathway}},
  journal = {Journal of Cancer},
  year = {2023},
  doi = {10.7150/jca.83708},
}
Figure